Concurrent with recent success using gene-modified T cells for immunotherapy, is exciting progress in the refinement, scale-up and clinical applications of non-gene modified immune effector cells. The speakers in this session will provide state-of-the-art reviews of laboratory methodologies, manufacturing and production challenges, clinical data and the therapeutic potential of autologous and allogeneic natural killer (NK) cells, dendritic cells (DC) and T cells to treat malignant diseases.
Appreciate the therapeutic potential of non-gene modified immune effector cells for the treatment of malignant diseases.
Identify the technical challenges and methodologies to optimize immune cell populations for adoptive immunotherapy.
Recognize the future directions and opportunities for broader applications of cell-based immunotherapies.